SINOVAC Board of Directors Provides Update on Special Dividend Payment and Commitment to Delivering Value to All Shareholders




SINOVAC Board of Directors Provides Update on Special Dividend Payment and Commitment to Delivering Value to All Shareholders

Accelerates payment of previously announced special cash dividend of US$55.00 per common share

Decides to declare second special cash dividend of US$19.00 per common share

Intends to declare third special cash dividend between US$20.00 – US$50.00 per common share

Adopts new dividend policy to regularly return cash to shareholders

BEIJING–(BUSINESS WIRE)–The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced several important decisions to deliver sustainable value to shareholders and strengthen the Company’s governance framework.

Currently, a dissenting investor group led by Advantech/Prime Success and Vivo Capital (together known as the “Dissenting Investor Group”) and certain former illegitimate board (the “Imposter Board”) members are attempting to distract SINOVAC shareholders with lawsuits, false claims and empty promises as part of a hostile attempt to remove the SINOVAC Board – which was recently installed by the Privy Council order and in accordance with Antiguan law – with the goal to move SINOVAC backward and continue to entrench themselves. In contrast, the SINOVAC Board is taking clear actions to restore fairness and deliver value to ALL SINOVAC shareholders.

Key Updates and Commitments

1. Acceleration of Special Dividend Payment:
   
   The SINOVAC Board has authorized Audit Committee Chair Sven H. Borho to accelerate the payment of the previously announced special dividend of US$55.00 per common share, which it now expects to be paid on or about July 7, 2025, in advance of the Special Shareholder Meeting (“SSM”), subject to compliance with and approval by NASDAQ and the outcome of the Advantech/Prime Success lawsuit recently filed in New York.

   Contrary to claims by the Dissenting Investor Group, the date of the SSM on July 8 was driven by when SAIF filed the requisition for the meeting, and per Antiguan law, the SSM has to be held by July 8 unless SAIF agrees to resend their request. The SINOVAC Board has asked SAIF to reissue the request so that the SSM can be delayed until after July 9, but received no reply. Nevertheless, since establishing the date for the SSM, the Board has been working to accelerate the payment of the special dividend, demonstrating our commitment to restoring fairness. Yet the SINOVAC Board has encountered frequent interference by the Dissenting Investor Group, including the new lawsuit filed by Advantech/Prime Success on June 12.

   The SINOVAC Board’s acceleration of this payment is to ensure that, regardless of the outcome of the SSM, all valid shareholders will receive the special dividend payment as an initial corrective step in ensuring fair and equitable distributions of dividends to all SINOVAC shareholders.

2. Decision to Declare an Additional Dividend:
   In its April 1 announcement, the SINOVAC Board stated its intention to make additional distributions to shareholders as part of its effort to catch up common shareholders with distributions that were paid out to subsidiary shareholders (primarily the Dissenting Investor Group). The SINOVAC Board has since learned that the Company’s operating subsidiary, Sinovac Life Sciences Co., Ltd. (“SLS”), continued issuing additional dividends to its minority shareholders in the second half of 2024 while the Company was still under the control of the Imposter Board, with SINOVAC’s valid shareholders receiving nothing. Thus, the current SINOVAC Board has decided to declare a second special cash dividend after the SSM of US$19.00 per common share. If the legal proceedings on PIPE shares conclude with cancellation of PIPE shares, the valid SINOVAC shareholders will receive an additional US$3.73 per common share.

3. Adoption of a New Dividend Policy:
   The SINOVAC Board has adopted a policy regarding the regular payment of dividends out of surplus cash above the amount needed to properly capitalize the Company and fund its operations. Based on a preliminary analysis, the SINOVAC Board believes this amount is between US$20.00 – US$50.00 per common share that could be distributed to SINOVAC shareholders in the future.

   This policy is another step the SINOVAC Board is taking to make common shareholders whole and restore fairness and equity for all valid shareholders who were previously excluded from distributions. The Imposter Board allowed SLS to distribute over US$2 billion in dividends to minority shareholders but determined not to distribute a fair share to the valid common shareholders of SINOVAC. Under the current SINOVAC Board, this practice will stop – if there are distributions made at the subsidiary level, we will ensure they will be fairly distributed to all SINOVAC shareholders.

4. Commitment to an Annual Meeting in Q2 of 2026:
   
   The current SINOVAC Board directors are focused on completing the SSM and fighting for fairness for ALL shareholders, in furtherance of the Company’s best interests. Following the SSM, the SINOVAC Board will immediately turn towards improving SINOVAC’s corporate governance. To that end, the SINOVAC Board is committed to holding an annual meeting of shareholders in the second quarter of 2026. Ahead of this meeting, the SINOVAC Board will introduce additional director nominees for election, ensuring the full slate has the combined skills, qualifications, and experience to best serve and oversee the Company’s strategy and operations, with the integrity and fiduciary commitment to fairly represent and make decisions in the best interests of the Company, while duly considering the interests of all SINOVAC shareholders. The slate is expected to include one or more representatives from SINOVAC’s management team, ensuring that the SINOVAC Board and management remain aligned on the Company’s long-term strategic goals.

5. Exploration of Other Listing Venues:
   
   The SINOVAC Board also authorized the formal exploration of a future listing of SINOVAC shares on The Stock Exchange of Hong Kong and potentially other exchanges in order to stimulate liquidity, mitigate geopolitical risk, and maximize long term shareholder value.

Your Vote Will be Important

As previously announced, the Company intends to imminently file its definitive proxy materials with the Securities and Exchange Commission (SEC) for the Special Meeting of Shareholders to be held on Wednesday, July 9, 2025 at 8:00 a.m. China Standard Time (Tuesday, July 8, 2025 at 8:00 p.m. Atlantic Standard Time). Valid shareholders of record as of the close of business on May 19, 2025 are entitled to vote at the meeting.

Your vote on or before July 9 will be about the future of SINOVAC, your receipt of your make-whole dividend payments in the near-term, and the long-term value of your investment.

Your vote will be critical to ensuring that SINOVAC remains on the path to stability, growth, and value creation for all shareholders.

About SINOVAC

Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases.

SINOVAC’s product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, etc.

The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine under “Category 1 Preventative Biological Products” and commercialized in China in 2016. In 2022, SINOVAC’s Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO.

SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government’s vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program.

SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations.

Important Additional Information and Where to Find It

In connection with SINOVAC’s Special Meeting, SINOVAC will file with the U.S. Securities and Exchange Commission (“SEC”) and mail to shareholders of record entitled to vote at the Special Meeting a proxy statement and other documents, including a WHITE proxy card. SHAREHOLDERS ARE ENCOURAGED TO READ THE PROXY STATEMENT AND ALL OTHER RELEVANT DOCUMENTS WHEN FILED WITH THE SEC AND WHEN THEY BECOME AVAILABLE BECAUSE THOSE DOCUMENTS WILL CONTAIN IMPORTANT INFORMATION. When filed with the SEC, the proxy statement and WHITE proxy card will also be mailed to shareholders of record. Investors and other interested parties will be able to obtain the documents free of charge at the SEC’s website, www.sec.gov, or from SINOVAC at its website: https://www.sinovac.com/en-us/Investors/sec_filings. You may also obtain copies of SINOVAC’s proxy statement and other documents, free of charge, by contacting SINOVAC’s Investor Relations Department at ir@sinovac.com. Other information regarding potential participants in any such proxy solicitation will be filed by SINOVAC.

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions, including the Company’s statements related to the Compliance Plan, and timing and actions taken to regain compliance with Nasdaq listing rules. Such statements are based upon the Company’s current expectations and current market and operating conditions and relate to events that involve known or unknown risks, uncertainties and other factors, including without limitation risks, uncertainties and factors related to the timing of engaging independent auditors and completion of the audits of required fiscal periods, completion and filing of the 2024 Annual Report, the Compliance Plan, and actions taken to regain compliance with the Nasdaq listing rules, all of which are difficult to predict and many of which are beyond the Company’s control, which may cause the Company’s actual results, performance or achievements to differ materially from those in the forward-looking statements. Further information regarding these and other risks, uncertainties or factors is included in the Company’s filings with the U.S. Securities and Exchange Commission. The Company does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law.

Contacts

Investors and Media
FGS Global

Sinovac@fgsglobal.com

X-Atlas/Orion: Xaira Therapeutics Unveils Largest Publicly Available Genome-Wide Perturb-seq Dataset to Power Next-Generation AI for Biology




X-Atlas/Orion: Xaira Therapeutics Unveils Largest Publicly Available Genome-Wide Perturb-seq Dataset to Power Next-Generation AI for Biology

• Xaira is an integrated biotechnology company built to deliver on the promise of AI to help transform the drug discovery and development process

• The company released a preprint with details of its robust platform, Fix-Cryopreserve-ScRNAseq (FiCS) Perturb-seq, specifically designed for generating high-quality data at scale; and simultaneously provided the largest public release to date of this type of data, X-Atlas/Orion

• Xaira also reported details of its method to identify dose-dependent genetic effects within this kind of data

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Xaira Therapeutics today announced a significant leap forward in developing AI-driven virtual cell models with the release of “X-Atlas/Orion,” the largest publicly available Perturb-seq atlas. This extensive dataset was made possible by Xaira’s concurrently introduced “Fix-Cryopreserve-ScRNAseq” (FiCS) Perturb-seq platform, a highly scalable technology designed for large-scale data generation. These combined advancements are poised to accelerate the development of biological foundation models and unlock new frontiers in biological discovery and therapeutic development.

The rapid progress of single cell technology has spurred the creation of foundation models aimed at deciphering complex biological processes. While these models hold immense potential for creating AI-driven virtual cells, their advancement has been hampered by the scarcity of large-scale, high-quality perturbation data. Xaira’s FiCS Perturb-seq platform, which leverages the Chromium platform from 10x Genomics, delivers the sensitivity, scalability and reproducibility essential for generating high-quality perturbational data. Xaira’s innovative approach solves logistical challenges associated with profiling large numbers of cells, effectively captures perturbation-induced transcriptomic changes and accurately recapitulates known biological pathways and protein complexes. The X-Atlas/Orion dataset itself comprises 8 million cells, targeting all human protein-coding genes, with deep sequencing of over 16,000 unique molecular identifiers (UMIs) per cell, allowing for the discovery of biological phenotypes from a wide range of genetic perturbations.

“This industrialized platform and the Orion dataset will empower scientists to build more predictive models of complex biology,” said Ci Chu, vice president of early discovery at Xaira and senior author of the preprint. “We believe this will help us better understand disease biology and discover drug targets.”

One of the most significant advances is Xaira’s method to detect dose-dependent genetic effects, a more refined way of understanding how gene activity changes with the intensity of a given intervention. Traditionally, scientists viewed Perturb-seq gene knockdowns as an “on” or “off” switch. The Xaira scientists showed that the amount of single guide RNA (sgRNA) detected in each cell can be used to measure how strongly a gene is suppressed, offering a much more detailed picture of genetic function. This methodology offers a refined framework to enhance the predictive power and biological insight of future causal models by incorporating perturbation strength as a continuous variable.

“This platform provides the scale and quality needed to model how cells respond across conditions, which is a crucial step toward training the first generation of virtual cell models,” said Bo Wang, SVP and head of biomedical AI for Xaira Therapeutics. “With this foundation, we’re better equipped to uncover disease mechanisms and design smarter therapies.”

This publication caps a landmark year for Xaira since its launch in April 2024. In October 2024, Dr. David Baker, Xaira co-founder, received the Nobel Prize in Chemistry alongside Drs. Demis Hassabis and John Jumper of Google DeepMind for pioneering AI-driven advancements in protein structure prediction and novel protein design. The Xaira team is working to advance these models while developing new methods that can connect the world of biological targets and engineered molecules to the human experience of disease.

Access the Dataset:

X-Atlas/Orion is now publicly available here: https://doi.org/10.25452/figshare.plus.29190726

Read the Preprint:

FiCS Perturb-seq and X-Atlas/Orion publication: https://www.biorxiv.org/content/10.1101/2025.06.11.659105v1

About Xaira Therapeutics

Xaira Therapeutics is an integrated biotechnology company driving advances in artificial intelligence to learn the language of life and transform how we treat disease. The company seeks to rethink the drug discovery and development process from end-to-end by bringing together leading talent across three core areas: machine learning research to better understand biology, expansive data generation to power new models, and robust therapeutic product development to treat disease. Xaira is headquartered in the San Francisco Bay Area.

Contacts

press@xaira.com

ChoiceSpine™ Announces Launch of ChoiceSpine™ App for Surgical Use with eCential Robotics Op.n™ Robotic and Navigation Platform




ChoiceSpine™ Announces Launch of ChoiceSpine™ App for Surgical Use with eCential Robotics Op.n™ Robotic and Navigation Platform

KNOXVILLE, Tenn. & FRANKLIN, Tenn.–(BUSINESS WIRE)–#ChoiceSpine–ChoiceSpine LLC, a privately-held U.S. spinal implant company, in collaboration with eCential Robotics, a leading innovator in surgical robotics, proudly announces the launch of the ChoiceSpine™ application (App) for surgical use on the eCential Op.n™ robotic and navigation platform.

This milestone represents a significant leap forward in spine surgery, integrating advanced navigation and robotic-assisted technology to support both open and minimally invasive spine procedures. The ChoiceSpine™ application will function on the Op.n™ platform, working in tandem with ChoiceSpine’s core spine portfolio. This includes the following ChoiceSpine Navigation-enabled instrumentation:

• Thunderbolt™ MIS Pedicle Screw System
• Thunderbolt™ Extended Tab MIS Pedicle Screw System
• Lancer™ Open Pedicle Screw System

The Op.n™ platform enhances the precision of implant placement and reduces radiation exposure while improving procedural efficiency.

Steve Ainsworth, Ph.D., ChoiceSpine’s Co-President, said, “Robotics has become a significant competitive advantage in modern healthcare, and we are thrilled to expand our presence in this space through our collaboration with eCential Robotics. By combining the advanced capabilities of the eCential Robotics platform with our comprehensive spinal implant portfolio, we are setting a new standard in spine surgery.

“This strategic partnership enables us to deliver innovative solutions that enhance patient outcomes and improve procedural efficiency. It exemplifies our commitment to bringing technically superior spinal devices to the market—and doing Spine the Right Way℠.”

“We are excited to see our APP ecosystem growing, delivering on our vision to provide procedural option choices for surgeons while minimizing the capital investment cost for medical facilities,” commented Clement Vidal, CEO of Surgical Robotics.

The release of the new ChoiceSpine App marks another significant milestone for eCential Robotics in democratizing access to spinal Robotic surgery.

About eCential Robotics

Founded by Stéphane Lavallée and part of the Grenoble Haventure network, eCential Robotics is a French and US-based company specializing in surgical robotics. Powered by a unique OPEN ecosystem fueled by APPS, it has developed an implant-agnostic, modular multi-technology, and scalable robotic and navigation platform aiming to increase robotic capabilities, enable decentralized innovation through third-party development, and give surgeons and hospitals maximal control over their clinical, technological, and capital investment strategy. With over 100 patents and seven trademarks, and thanks to multiple partnerships established with implant manufacturers, tech companies, research labs, and surgeons, eCential Robotics is positioned as a leader in the fast-growing surgical robotics market and aspires to become the world leader in open robotic platforms.

Please visit http://www.ecential-robotics.com and follow us on LinkedIn (eCential Robotics).

About ChoiceSpine

ChoiceSpine LLC is a privately held spinal device company located in Knoxville, TN, and is owned by Altus Capital Partners. ChoiceSpine prides itself on providing excellent products that aim to improve people’s lives through a positive customer experience. Here at ChoiceSpine, we offer a variety of surgeon-focused product lines designed to be safe, efficient, and easy to use. By focusing on a collaborative team approach with physicians and industry partners, ChoiceSpine continues to deliver upon product commitments, maintain cutting-edge research and development, and bring technically superior products to the forefront of the spinal implant industry. For more information, please visit www.choicespine.com.

Contacts

Media contact
Matthieu VILLE

matthieu.ville@ecential-robotics.com

Benjamin COLAS

Investor relations

benjamin.colas@ecential-robotics.com

Media contact

Ron Moore

Sr. Director of Marketing

865-246-3333

rmoore@choicespine.com

Zetagen Therapeutics Announces Peer-reviewed Publication of In-Vivo Dose Optimization Findings for ZetaMast™ (Zeta-MBC-005) for Triple Negative Breast Cancer Liver Metastases




Zetagen Therapeutics Announces Peer-reviewed Publication of In-Vivo Dose Optimization Findings for ZetaMast™ (Zeta-MBC-005) for Triple Negative Breast Cancer Liver Metastases

(Patients with disseminated metastatic disease from breast cancer are likely to have liver involvement in >50% of cases at some point during disease progression. These patients have poor prognosis; and, when treated with the standard of care systemic therapy they have a median survival of <9-months.)

• Zetagen identifies two concentrations of ZetaMast™ (Zeta-MBC-005) which were most effective in treating metastatic triple negative breast cancer (TNBC) in the liver
• ZetaMast™ (Zeta-MBC-005) exhibits significant decrease in tumor volume (4-fold) vs. control Doxorubicin
• ZetaMast™ (Zeta-MBC-005) demonstrates a 3.9-fold increase in survival rate over control Doxorubicin with no lung or brain metastases.

SYRACUSE, N.Y.–(BUSINESS WIRE)–Zetagen Therapeutics, a private, clinical-stage, biopharmaceutical company developing first-of-its-kind targeted therapies for primary and metastatic breast cancer, announced today the peer-reviewed publication in PLOS-One of their dose optimization in-vivo study results of ZetaMast™ (Zeta-MBC-005).

Zetagen identified two concentrations of ZetaMast™ (Zeta-MBC-005) which demonstrated superior effectiveness, reduction in tumor burden, and increased survival rate over control Doxorubicin.

“Patients with disseminated metastatic breast cancer involving the liver, face a poor prognosis and new approaches are urgently needed,” stated Debasish Tripathy, MD, Professor and Chairman, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX. “Although some therapies have been designed for direct administration for liver metastases, they have not demonstrated efficacy in significantly improving survival. ZetaMast™ is an innovative therapeutic approach that has demonstrated systemic biological effects potentially extending beyond liver metastases in preclinical models, offering promising potential to enhance outcomes in this setting.”

ZetaMast™ (Zeta-MBC-005) Increased Survival in a Mouse Xenograft Liver Metastases Model. The 4T1, TNBC cell line, tagged with luc2 luciferase (4T1-luc2), was implanted directly into the liver of BALB/c mice. Seven days after tumor inoculation, mice were treated with various concentrations via a single administration of ZetaMast™ (Zeta-MBC-005) (30-, 60-, 120-, 180-, 240-, or 480-μg) in combination with 5-mg/kg doxorubicin. Mice in the Control group received 5 mg/kg of doxorubicin and the ZetaMast™ (Zeta-MBC-005) carrier without Zetagen’s small molecule, administered every 72-hours.

ZetaMast™ (Zeta-MBC-005) has the ability to deliver Zetagen’s small molecules intratumorally as well as other therapies, avoiding off-target side effects.

“Effective locoregional therapies are likely the key to reducing breast cancer mortality for patients with disseminated metastatic disease and increasing 5-year survival above 31%. If treatments like ZetaMast™ (Zeta-MBC-005) can be given when and where needed, increasing the duration of overall tumor control, which may be enough to tip the balance towards a favorable impact on survival,” stated Bryan S. Margulies, MS, Ph.D., CSO of Zetagen.

To view the ZetaMAST™ (Zeta-MBC-005) dose optimization study results go to https://doi.org/10.1371/journal.pone.0323621.

About ZetaMAST™ (Zeta-MBC-005)

ZetaMast™ (Zeta-MBC-005) is a proprietary drug eluting carrier designed for locoregional administration, controlled release of two small molecules in the treatment of multifocal, unresectable, liver metastases from breast cancer with the potential to increase survival rates.

The USPTO has granted Zetagen a “Composition of Matter” patent for ZetaMast™ (Zeta-MBC-005), and Zetagen has also submitted a filing to the FDA for Orphan Drug Designation.

Zetagen is finalizing preparations for an FDA IND submission this fall, with a Phase 1b clinical trial set to commence early 2026.

About Zetagen Therapeutics

Zetagen has three novel drugs in development, ZetaMet™ (Zeta-BC-003), for the treatment of metastatic breast cancer to bone, ZetaMast™ (Zeta-MBC-005) for breast cancer liver metastases (BCLM), and (NEW) ZetaPrime™ (Zeta-PBC-007) for the treatment of primary HR+ breast cancer, all with inspiring results. To learn more, visit www.zetagen.com.

The FDA has acknowledged Zetagen’s innovative research with multiple Breakthrough Designations, notably ZetaMet™ (Zeta-BC-003). Under FDA and Health Canada (HC) approval through the Expanded Access (Compassionate Use) programs, Zetagen has treated eight patients with ZetaMet™ (Zeta-BC-003), with results featured in several peer-reviewed journals. Furthermore, Zetagen has completed enrollment for its Phase 2a open-label clinical trial focused on treating metastatic breast cancer in the spine.

Zetagen Upcoming Events

Zetagen will attend the 2025 San Antonio Breast Cancer Symposium (SABCS).

Forward-Looking Statements

This press release contains certain forward-looking statements with the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions. Source: Zetagen Therapeutics, Inc.

Contacts

Investor Inquiries:
Zetagen Therapeutics, Inc.

Email: InvestorRelations@zetagen.com

Biocytogen Responds to Harbour BioMed’s Patent Claims: RenNano® is an Independently Developed Platform with Distinct Innovation and Full Legal Standing




Biocytogen Responds to Harbour BioMed’s Patent Claims: RenNano® is an Independently Developed Platform with Distinct Innovation and Full Legal Standing

BEIJING–(BUSINESS WIRE)–In response to Harbour BioMed’s recent press release regarding a procedural development in their ongoing legal claim, Biocytogen issues the following statement:

Biocytogen stands by its core values of independent innovation, respect for intellectual property, and a commitment to fair competition. The RenNano® platform is the result of independent, original R&D, based on Biocytogen’s proprietary genome editing technologies. Its technical principles, design strategy, and IP scope are fundamentally different from the patents in dispute.

120 vs. 9 – A Significant Technical Divide of RenNano® Platform; Biocytogen Will Resolutely Take Legal Actions to Protect Its Rights

The RenNano® platform employs a large-fragment knock-in strategy that incorporates over 120 human V genes in situ, enabling a complete and functional human heavy chain antibody repertoire. In stark contrast, Harbour BioMed’s HCAb platform introduces only 9 V genes through a small-fragment transgenic approach. This key difference reflects not only divergent technical strategies but also the depth, innovation, and translational potential of Biocytogen’s antibody discovery platforms.

The decision referenced in Harbour BioMed’s PR involves a procedural ruling on jurisdiction only and does not address the substance of the patent infringement case. Furthermore, the CNIPA’s affirmation of patent validity is a routine administrative process that does not imply infringement. The underlying lawsuit has not yet entered the trial phase.

Biocytogen is currently evaluating all legal options and will resolutely defend its IP rights and scientific reputation. The RenNano® platform has been fully validated and is supported by a robust portfolio of domestic and international patents, clearly documenting its originality and independence.

We remain confident in:

• The technical integrity and legal foundation of the RenNano® platform;
• The non-infringement of any third-party IP;
• Our continued leadership in antibody discovery and therapeutic innovation.

According to public records, the Chinese patent related to Harbour BioMed’s HCAb platform is set to expire on July 22, 2025, further underscoring the short-sighted nature of any speculative claims. Regardless, Biocytogen will continue to uphold its rights, ensure business continuity, and deliver transformative technologies for global partners and patients.

Any misleading allegations or speculative narratives will not deter our team from advancing the RenMice® platform series with world-class innovation and delivering on our mission to accelerate therapeutic discovery.

Key Technical Differences Between Biocytogen’s RenNano® Platform and Harbour BioMed’s HCAb Platform

• Biocytogen RenNano® Platform: Uses large-fragment knock-in technology to replace mouse genes with over 120 human V genes in situ, resulting in a full and functional human heavy chain variable region genomic repertoire.
• Harbour BioMed HCAb Platform: Introduces only 9 V genes using small-fragment transgenic approaches.

About Biocytogen

Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® (RenMab™/ RenLite®/ RenNano®/ RenTCR-mimic™ ) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of December 31, 2024, approximately 200 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company’s sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit http://en.biocytogen.com.cn.

Contacts

Biocytogen Contacts
Antibody platform and assets: BD-Licensing@biocytogen.com
Preclinical models and services: info@biocytogen.com
Media: marketing@biocytogen.com

New Vizient Survey Finds Drug Shortages Cost Hospitals Nearly $900M Annually in Labor Expenses




New Vizient Survey Finds Drug Shortages Cost Hospitals Nearly $900M Annually in Labor Expenses

IRVING, Texas–(BUSINESS WIRE)–Vizient^® today announced its updated analysis of the financial impact of drug shortages for hospitals to their workforce and budgets. The new survey, “Beyond the Shortage: The Hidden Cost of Drug Supply Chain Disruptions,” revealed that in 2023, hospitals across the U.S. spent roughly 20 million hours managing a range of drug shortages, which translates to nearly $900 million annually in labor costs—more than double the labor costs reported of just under $360 million in the 2019 survey.

“The new survey’s findings illustrate how staffing burdens have surged since 2019, demanding more time and resources—especially in pediatric facilities—to simply navigate drug shortages,” said Nikola Markoski, director, pharmacy sourcing strategic solutions & analytics for Vizient. “If you add in the cost of more expensive alternative therapies, direct purchases outside the hospital’s traditional channels, medication errors and cancelled or delayed medical procedures, the actual total cost of managing drug shortages for hospitals far exceeds the nearly $900 million figure for additional labor.”

Overall, the 132 respondents who participated in the 2024 survey monitored an average of 43 drug shortages and a maximum of 70 over the course of 2023. Pediatric facilities monitored at least 25% more shortages than general facilities due to the high risk and complexity of pediatric populations coupled with treatment often requiring a mix of both adult-approved drugs and pediatric-approved drugs.

Additional findings from the survey include:

• 43% of respondents indicated medication errors that had occurred were related to drug shortages, up from 38% from the 2019 survey.
• 27% of respondents reported that drug shortages caused disruptions in patient care. Outpatient infusion services were most affected with 41% of patient cases omitted, missed or delayed.
• Planned medical procedures were also impacted by shortages, with disruptions reported in 32% of cases, followed by hospital admissions at 22%.

The findings of the updated survey, which focused on the period of January through December 2023, highlight the ongoing direct financial challenges caused by drug shortages, defined as an increase in hospital operating budget or labor expenses associated with drug shortages.

To help providers address the financial pressures related to drug shortages, Vizient offers strategic solutions through its contracting capabilities and pharmacy programs such as the Novaplus Enhanced Supply and Novaplus Enhanced Supply Reserve. Since their inception in 2021, Vizient clients have accessed over 4 million additional units of onshore manufacturer inventory across more than 200 high-impact critical molecules, including many frequently reported in shortage. This expanded access has played a vital role in improving medication availability, maintaining continuity of care and reinforcing resiliency across the supply chain.

In addition to medication access, clients who participate in these programs avoid the financial burden of shortages by mitigating labor costs associated with sourcing and managing alternatives and reducing the need for emergency purchasing. Since 2023, Vizient estimates the programs have generated nearly $300 million in inventory cost avoidance for participating clients.

“While our supply assurance strategies are making a significant difference in practice, the findings of this survey reflect on the work that remains to be done, which is why Vizient continues to expand its strategies for pharmaceuticals and other critical supplies,” said Mittal Sutaria, PharmD, senior vice president, pharmacy contract and program services for Vizient.

Read the full report here.

About Vizient, Inc.

Vizient, Inc., the nation’s largest provider-driven healthcare performance improvement company, serves more than 65% of the nation’s acute care providers, including 97% of the nation’s academic medical centers, and more than 35% of the non-acute market. The Vizient contract portfolio represents $140 billion in annual purchasing volume enabling the delivery of cost-effective, high-value care. With its acquisition of Kaufman Hall in 2024, Vizient expanded its advisory services to help providers achieve financial, strategic, clinical and operational excellence. Headquartered in Irving, Texas, Vizient has offices throughout the United States. Learn more at www.vizientinc.com.

Contacts

Media contact

Donna Ledbetter

972-830-6321

Donna.ledbetter@vizientinc.com

June Health Launches to Redefine Women’s Health as a Strategic Employer Benefit




June Health Launches to Redefine Women’s Health as a Strategic Employer Benefit

Employers in Canada can now close the care gap for women in the workforce through timely access to expert-led, integrated care and convenient treatment options

TORONTO–(BUSINESS WIRE)–#JuneHealth—June Health, a comprehensive virtual care platform built specifically to serve women’s health needs, today announced its national launch. June Health offers coordinated, clinically rigorous medical and lifestyle-oriented care tailored to perimenopause and midlife health. The multidisciplinary solution, which is the first to provide benefits navigation and include pharmacy and marketplace integrations, is available to individuals and offered as a modern workplace benefit for progressive employers, insurers, and health provider networks.

Women over 40 represent the fastest-growing segment of the workforce, yet most health benefit programs still fail to directly address the complex and interconnected health needs of this population. June Health changes this through a convenient digital platform that provides virtual clinical care, on-demand treatment and benefits coordination, AI-powered navigation, a digital pharmacy, expert-vetted health supplements, and women’s mental health support – all in one seamless user experience.

“Untreated perimenopause is a silent productivity and retention crisis that hits companies where it hurts – in absenteeism, burnout, and talent attrition. June is purpose-built to solve this clinically, digitally, and operationally at scale,” said Lori Casselman, founder and CEO of June Health. “The unfortunate reality is that timely access to expert midlife care is out of reach for many women, and employers have a tremendous opportunity to be part of the solution. It’s a necessary evolution of healthcare benefits, which are built to support the health needs of an entire workforce.”

A Platform Designed for Employers. A Model Built for Real Life.

Unlike generic telehealth or symptom-based consumer apps, June Health delivers a full-stack care model centered around managing the common and often debilitating health symptoms associated with perimenopause. The platform combines the convenience of virtual care with the credibility of a multidisciplinary team of health experts, including physicians, nurse practitioners, dietitians, mental health professionals, and naturopaths – trained and credentialed in the science and lived experience of women.

For employers, June offers a ready-to-deploy benefit that complements existing health plans, reduces healthcare costs, and drives measurable workforce ROI. With the Canadian economy losing an estimated $3.5 billion annually due to unaddressed menopause symptoms, June Health helps employers tackle one of the last remaining frontiers in inclusive, high-impact benefits design.

“Perimenopause can last up to 10 years, presents with over 40 common symptoms, and affects everything from cognitive function to cardiovascular health,” said Dr. Romy Nitsch, Medical Director at June Health. “It’s time we stopped treating this as a lifestyle issue and started addressing it as the complex medical phase it truly is. Our team delivers evidence-based care that reflects the whole woman – her biology, her stress load, and her full healthcare needs.”

How June Works: A Tech-Enabled Ecosystem for Women’s Health

June isn’t just virtual care, it’s a connected care ecosystem. The platform’s unique service architecture ensures that women receive timely, personalized, empathetic, proactive, and continuous support throughout their health journey. Key features include:

• Intelligent Triage and Clinical Matching – A proprietary intake system that rapidly assesses symptoms and connects members to the right specialists at the right time.
• Multidisciplinary Clinical Team – Access to a co-ordinated team of certified women’s health experts, including physicians, naturopaths, registered dietitians, mental health professionals, weight management and fitness specialists, and more. Delivered through convenient virtual appointments tailored to busy lives.
• Dedicated Care Coordinators – Personal care advocates help women navigate coverage, treatment options, and provider referrals, taking the friction out of care.
• Integrated Pharmacy and Supplement Marketplace – Curated, clinically-backed products delivered to members’ doors via seamless in-app ordering.
• Community and Education Hub – On-demand programs, peer support, and trusted resources designed for the midlife experience.
• AI-Powered Assistant: Ask June – A 24/7 smart concierge offering real-time guidance, symptom tracking, care navigation, and escalation to human care when needed.

Closing the Gap for Good

More than 10 million women in Canada are navigating midlife health changes, many in silence and without the support of trained clinicians who understand the issues they face. June Health exists to change that, not only by delivering personalized, expert care to women, but by helping forward-looking employers become part of the solution.

A Founding Story Rooted in Lived Experience and Deep Market Insight

June Health was founded by Lori Casselman, an experienced healthcare executive who saw firsthand how the healthcare system and employee benefit models have failed to address the serious health symptoms women navigate through midlife. With leadership experience at Sun Life, Telus Health, and as former Chief Health Officer at League, Lori recognized a pressing opportunity to build a more personalized, clinically rigorous, and scalable solution.

To bring this vision to life, she partnered with Dr. Romy Nitsch, MD, MHSc, Medical Director and Deputy Department Head, Obstetrics & Gynecology, and Associate Professor, Faculty of Medicine, Queen’s University; and Fazlin Bandali, a seasoned operator with a decade of experience at Shopify, following several early-stage tech startup roles. Together, this multidisciplinary team brings expertise across healthcare and insurance, clinical excellence, and digital product innovation to uniquely position June Health to lead this category.

Employers that want to offer June Health as a workplace benefit can contact June Health at support@junewomenshealth.com or www.junehealth.care.

About June Health

June Health is Canada’s first fully integrated virtual care platform dedicated to midlife women’s health. Purpose-built to support employers, health plans, and providers, June offers end-to-end clinical support, AI-powered care navigation, pharmacy integration, and a curated digital health marketplace. June is on a mission to close the midlife care gap and make personalized, expert care accessible for every woman — whenever and wherever she needs it.

To learn more, visit junehealth.care. Follow us on LinkedIn.

Contacts

Media Contact:
Jodi Echakowitz

Boulevard Public Relations

jodi@boulevardpr.com

Arialys Therapeutics Publishes Preclinical Data in Nature Communications Supporting ART5803 as a First-in-Class Precision Therapeutic for Anti-NMDA Receptor Autoimmune Neuropsychiatric Disease




Arialys Therapeutics Publishes Preclinical Data in Nature Communications Supporting ART5803 as a First-in-Class Precision Therapeutic for Anti-NMDA Receptor Autoimmune Neuropsychiatric Disease

Study highlights novel monovalent therapeutic antibody’s ability to block NMDA receptor internalization and reverse disease phenotypes in primate models

LA JOLLA, Calif.–(BUSINESS WIRE)–#ANRE—Arialys Therapeutics, a clinical-stage biotechnology company pioneering new precision medicines for autoimmune neuropsychiatric diseases, today announced the publication of preclinical data in Nature Communications demonstrating that its lead drug candidate, ART5803, effectively blocks the underlying disease mechanism in anti-NMDA receptor encephalitis (ANRE) and rapidly reverses behavioral symptoms in a non-human primate model. The findings support the continued clinical development of ART5803 as a first-in-class, targeted therapeutic. The company is currently completing Phase 1 safety studies for ART5803 and plans Phase 2 evaluation in anti-NMDA receptor encephalitis (ANRE) and autoimmune psychosis patients in the second half of 2025.

“This study underscores the promise of ART5803 to directly address neuropsychiatric disease caused by anti-NMDA receptor-targeting pathogenic antibodies,” said Peter Flynn, Ph.D. President and CEO of Arialys Therapeutics. “Despite our understanding of the disease mechanism and its severity, ANRE lacks an approved therapy. Further, there is a growing body of data identifying significant levels of anti-NMDA receptor autoantibodies in subpopulations of patients diagnosed with diseases that result in psychosis and dementia.”

“These data provide compelling evidence that ART5803 can directly block the pathogenic effect of autoantibodies that target the NMDA receptor, resulting in a rapid resolution of symptoms,” said Mitsuyuki (Mickey) Matsumoto, Ph.D., Chief Scientific Officer of Arialys Therapeutics and senior author of the paper. “Our detailed structural and functional analyses confirm that ART5803 precisely inhibits NMDA receptor internalization induced by the pathogenic autoantibodies, while preserving normal receptor function. In addition, our discovery of a potential molecular mimicry mechanism for anti-NMDA receptor autoantibody generation broadens the understanding of disease initiation and may inform future indication expansion for ART5803.”

Anti-NMDA receptor encephalitis (ANRE) is a rare, potentially lethal, poorly managed, and often misdiagnosed neurological disease. ANRE is caused by pathogenic autoantibodies that bind to and crosslink NMDA receptors in the brain, leading to receptor internalization and synaptic dysfunction. The result is a range of debilitating neuropsychiatric symptoms including psychiatric and behavioral alterations, cognitive decline, seizures, coma, and diminished autonomic function. A significant percentage of ANRE patients are pediatric, where NMDA receptor-specific autoantibodies can also result in neurological development deficits. There are no approved therapies for this disease, and current treatments rely on broadly immunosuppressive therapies, which are associated with delayed efficacy and significant side effects.

Recent findings have also identified anti-NMDA receptor autoantibodies in other neurological and psychiatric diseases such as schizophrenia, depression, bipolar disorder, and dementia. Arialys is planning clinical assessment of ART5803 in anti-NMDA receptor autoantibody-positive psychosis patients. The company is also currently testing patient samples using a proprietary high-throughput screen for autoantibodies to identify enriched disease indications and subpopulations for future clinical development.

ART5803 is a humanized, monovalent IgG1 antibody engineered to selectively bind the GluN1 subunit of the NMDA receptor without disrupting receptor function or causing internalization. In this study, ART5803 demonstrated the ability to potently block NMDA receptor internalization in cellular and neuronal models and reversed both molecular and behavioral hallmarks of disease in a novel marmoset model of ANRE. Notably, ART5803 exhibited rapid onset of action and was well tolerated in vivo. The publication also includes a detailed characterization of ART5803’s binding epitope, its mechanism of action, and population pharmacokinetic modeling supporting the feasibility of systemic administration in patients.

In addition to demonstrating the therapeutic potential of ART5803, the paper revealed a potential link between infections—specifically Toxoplasma gondii and certain bacterial pathogens—and the generation of pathogenic anti-NMDA receptor autoantibodies. Epitope mapping analysis identified regions of potential molecular mimicry between microbial proteins and the GluN1 subunit of the NMDA receptor, suggesting that infections could serve as environmental triggers for disease initiation. Notably, toxoplasmosis and bacterial infections are well-established risk factors for a range of neuropsychiatric conditions. These findings not only suggest a basis for disease pathogenesis but also support broader therapeutic opportunities for ART5803 across autoimmune neuropsychiatric disorders.

ART5803 is currently being evaluated in a Phase 1 clinical trial in healthy volunteers. In February 2025, Arialys announced completion of all single ascending dose (SAD) cohorts and initiation of multiple ascending dose (MAD) cohorts. The company expects to share initial clinical data in the second half of 2025 and initiate Phase 2 proof-of-concept studies.

The publication was completed in collaboration with researchers from Astellas Pharma Inc., University of California, Davis, Kitasato University School of Medicine, and Vanadro LLC.

About Arialys Therapeutics

Arialys was founded by investors Avalon Bioventures, Catalys Pacific and MPM to meaningfully expand the treatment possibilities for neuropsychiatric disorders driven by autoimmune disease. Using a combination of highly sensitive autoantibody detection, patient sampling and receptor structural biology, Arialys has developed a first-in-class precision therapy to specifically block pathogenic autoantibodies in the brain. Arialys is headquartered in La Jolla, California. For more information, visit www.arialysrx.com.

Contacts

Media: Jessica Yingling, Ph.D., Little Dog Communications Inc., jessica@litldog.com

Ferrer Receives FDA Fast Track Designation for FNP-223 in Progressive Supranuclear Palsy (PSP)




Ferrer Receives FDA Fast Track Designation for FNP-223 in Progressive Supranuclear Palsy (PSP)

BARCELONA, Spain–(BUSINESS WIRE)–Ferrer, a B Corp-certified international pharmaceutical company, has announced that FNP-223, a novel therapy in-licensed from Asceneuron and aimed at slowing the development of progressive supranuclear palsy (PSP), has received Fast Track designation from the US Food & Drug Administration (FDA). FNP-223, a new molecular entity in active development for PSP, is in an ongoing Phase 2 study to evaluate its safety, efficacy, and pharmacokinetics in adult patients with possible or probable PSP-Richardson syndrome (PSP-RS), the most common clinical variant of this neurodegenerative disease¹.

“We are thrilled to receive Fast Track designation from the FDA for FNP-223 in the treatment of PSP. Consistent with our purpose of using business to fight for social justice, we are committed to advancing this promising therapy as quickly as possible to benefit as many patients as possible,” said Mario Rovirosa, Chief Executive Officer of Ferrer.

Fast Track designation is a significant milestone in the drug development process. It is a program that offers the possibility of having more frequent meetings with the FDA to discuss the drug’s development, eligibility for Accelerated Approval and Priority Review if relevant criteria are met.

“This designation underscores the importance of expediting the development and review of FNP-223 to address critical unmet needs in patients with this rare and devastating disease,” said Marta Parmar, Ferrer’s Chief Quality, Regulatory and Pharmacovigilance Officer.

Progressive supranuclear palsy manifests in patients with symptoms such as difficulty speaking, imbalance, changes in gait, cognitive problems^2-4. PSP has a prevalence of approximately 5 cases per 100,000 people and primarily affects individuals over the age of 60³. The disease’s etiology is believed to be related to the abnormal accumulation of tau proteins in certain areas of the brain, leading to neurodegeneration^3,4. Preclinical models have demonstrated that FNP-223 can prevent the abnormal accumulation of tau proteins in neurons⁵. Ferrer now aims to show that this molecule is safe and effective in patients with PSP.

Oscar Pérez, Chief Scientific Officer of Ferrer, also expressed his enthusiasm: “Receiving Fast Track designation is a significant milestone in our journey to provide a transformative treatment for PSP. We are excited to advance our research and hopefully offer a new therapeutic option earlier for patients living with this challenging condition.”

About FNP-223

FNP-223 is a new orally administered chemical compound that functions as a reversible and substrate-competitive inhibitor of the O-GlcNAcase (OGA) enzyme⁵. Mechanistically, FNP-223 binds to the active site of OGA enzyme. As a result, the inhibitor prevents the substrate from accessing the catalytic pocket, thereby impeding the removal of O-GlcNAc modifications from natural client proteins such as the tau protein. Inhibiting O-GlcNAcase is expected to cause a rapid increase of O-GlcNAcylated (glycosylated) tau proteins, ultimately leading to a reduction in abnormal aggregated tau as neurofibrillary tangles (NFT) over a certain period⁵.

Bibliography:

1. ClinicalTrials.gov A Randomized, Double-blind, Placebo-controlled, Phase 2 Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 (Oral Formulation) to Slow the Disease Progression of Progressive Supranuclear Palsy (PSP) (PROSPER). ClinicalTrials.gov [Internet]. Available from: https://www.clinicaltrials.gov/study/NCT06355531.

2. Coughlin DG, Litvan I. Progressive supranuclear palsy: Advances in diagnosis and management. Parkinsonism Relat Disord. 2020 Apr;73:105-116. doi: 10.1016/j.parkreldis.2020.04.014. Epub 2020 May 25.

3. Agarwal S, Gilbert R. Progressive Supranuclear Palsy. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024. Available from: https://www.ncbi.nlm.nih.gov/books/NBK526098/.

4. Rowe JB, Holland N, Rittman T. Progressive supranuclear palsy: diagnosis and management. Pract Neurol. 2021;21(5):376-383. doi: 10.1136/practneurol-2020-002794.

5. Permanne B, Sand A, Ousson S, Nény M, Hantson J, Schubert R, et al. D. O-GlcNAcase Inhibitor ASN90 is a Multimodal Drug Candidate for Tau and α-Synuclein Proteinopathies. ACS Chem Neurosci. 2022 Apr 20;13(8):1296-1314. doi: 10.1021/acschemneuro.2c00057.

Contacts

gortizdez@ferrer.com
+34 936003779

Astoriom Appoints Brittany Jackson as CFO




Astoriom Appoints Brittany Jackson as CFO

Key appointment to lead the company’s financial strategy and support continued global growth in sample stability and biorepository storage solutions

ROCHDALE, England–(BUSINESS WIRE)–#Astoriom–Astoriom, a global leader in the R&D sample stability and biorepository storage industry, has appointed Brittany Jackson, FCCA as Chief Financial Officer (CFO). Brittany will work alongside the team to support the company’s financial and strategic initiatives and continue strengthening the organization’s growth in key global markets. Her appointment will also help to ensure sustainable success across its portfolio of sample stability storage, biorepository storage, disaster protection and recovery, as well as sample storage equipment and validation services.

Brittany brings extensive experience across biotech, manufacturing, education, hospitality and professional services, having previously held positions at companies including Protocol, Champion Accountants and The Manchester Metropolitan University. She is a Fellow of the Association of Chartered Certified Accountants (ACCA) and a commercially focused and results-driven leader, she has guided organizations through high-growth phases, operational transformation, and ownership transitions. Beyond finance, Brittany has also overseen IT, HR, legal, software, payroll, and quality functions, providing her with broad and strategic views of business management. By aligning these functions with Astoriom’s long-term goals, Brittany will help to ensure that operational efficiencies are maximized.

Lori A. Ball, CEO, Astoriom, said: “Brittany is a forward-thinking, purposeful leader. Her energy and expertise are invaluable and will be a great fit for our team. We are committed to ensuring sample assets are protected and preserved to support scientific R&D advancements, product safety and compliance, and innovation. With Brittany on board to help deliver Astoriom’s vision, I am confident we will continue to drive excellence across all aspects of the business and achieve impactful results for our customers worldwide.”

Brittany Jackson, CFO, Astoriom, said: “I’m enthusiastic about embedding finance as a true strategic partner to all stakeholders, innovating operational processes and building strong, empowered teams. With Astoriom’s mission to deliver industry-leading stability storage and biorepository services that create meaningful value for R&D companies worldwide, I’m excited to join the team at this pivotal moment of global expansion. I’m looking forward to supporting the company’s commercial growth while shaping operational maturity to ensure we continue to achieve organizational excellence.”

For more information about Astoriom’s team, please visit: https://www.astoriom.com/about/

ENDS

Contact Codon Communications for high-resolution images.

Contacts

Codon Communications
Dr Michelle Ricketts

+447789053885

michelle.ricketts@codoncommunications.com